Regeneron (REGN) and Sanofi Discontinue Phase 3 Libtayo Trial Due to Significant Improvement in Overall Survival in Patients with Certain Types of Lung Cancer


What’s going on with Regeneron?

Today, August 5, it was announced in a press release that Regeneron (REGN) and Sanofi (SNY) have stopped a phase 3 trial of the companies’ PD-1 inhibitor Libtayo in combination with doublet chemotherapy platinum. The trial was terminated prematurely due to “achievement of its primary endpoint of overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC)”. Before marketing this morning, REGN stock rose 3.19% to $ 599.50 per share.

What does this mean for REGN?

“Libtayo in combination with chemotherapy increased median overall survival at 22 months in patients with advanced non-small cell lung cancer, compared to 13 months with chemotherapy alone,” explained Miranda Gogishvili, MD, and oncologist in Tbilisi, Georgia.

“These data add to the growing body of evidence supporting Libtayo in advanced non-small cell lung cancer, which also includes the pivotal results of Libtayo monotherapy in cases of high PD-L1 expression,” Gogishvili continued . The Independent Data Monitoring Committee (IDMC) recommended that the trial be stopped early during an interim analysis specified by the protocol.

REGN has an overall score of 54. Find out what that means to you and get the rest of the leaderboard on REGN!

Regeneron Pharmaceuticals discovers, develops and markets products that fight eye disease, cardiovascular disease, cancer and inflammation. The company markets several products, including: Eylea, approved for age-related wet macular degeneration and other eye diseases; Praluent for lowering LDL cholesterol; Dupixent in atopic dermatitis, asthma and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancerology, as well as bispecific antibodies and antibody cocktails with other collaborators and independently.

To see Investors Observer full report on REGN Click here.

Leave A Reply

Your email address will not be published.